U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C22H30N4O2S2
Molecular Weight 446.629
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of THIOPROPERAZINE

SMILES

CN(C)S(=O)(=O)C1=CC2=C(SC3=C(C=CC=C3)N2CCCN4CCN(C)CC4)C=C1

InChI

InChIKey=VZYCZNZBPPHOFY-UHFFFAOYSA-N
InChI=1S/C22H30N4O2S2/c1-23(2)30(27,28)18-9-10-22-20(17-18)26(19-7-4-5-8-21(19)29-22)12-6-11-25-15-13-24(3)14-16-25/h4-5,7-10,17H,6,11-16H2,1-3H3

HIDE SMILES / InChI

Description
Curator's Comment: description was created based on several sources, including https://www.drugs.com/international/thioproperazine.html | https://www.ncbi.nlm.nih.gov/pubmed/13661859 | https://www.ncbi.nlm.nih.gov/pubmed/16777448 | https://www.ncbi.nlm.nih.gov/pubmed/1354163 | https://www.ncbi.nlm.nih.gov/pubmed/4379824 | http://eci2012.net/wp-content/uploads/2015/03/Majeptil-PM-En-160702.01-20Feb2015.pdf

Thioproperazine is a potent neuroleptic with antipsychotic properties. Thioproperazine has a marked cataleptic and antiapomorphine activity associated with relatively slight sedative, hypothermic and spasmolytic effects. It is virtually without antiserotonin and hypotensive action and has no antihistaminic property. It is used for the treatment of all types of acute and chronic schizophrenia, including those which did not respond to the usual neuroleptics; manic syndromes. Overdosage may result in severe extrapyramidal symptoms with dysphagia, marked sialorrhea, persistent and rapidly increasing hyperthermia, pulmonary syndrome, state of shock with pallor and profuse sweating, which may be followed by collapse and coma.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
0.45 nM [Ki]
1.2 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Majeptil

Approved Use

INDICATIONS. All types of acute and chronic schizophrenia, including those which did not respond to the usual neuroleptics; manic syndromes.
Primary
Majeptil

Approved Use

INDICATIONS. All types of acute and chronic schizophrenia, including those which did not respond to the usual neuroleptics; manic syndromes.
Primary
Majeptil

Approved Use

INDICATIONS. All types of acute and chronic schizophrenia, including those which did not respond to the usual neuroleptics; manic syndromes.
Doses

Doses

DosePopulationAdverse events​
160 mg 1 times / day multiple, oral
Highest studied dose
Dose: 160 mg, 1 times / day
Route: oral
Route: multiple
Dose: 160 mg, 1 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
30 mg 3 times / day multiple, oral
Recommended
Dose: 30 mg, 3 times / day
Route: oral
Route: multiple
Dose: 30 mg, 3 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Disc. AE: Excitement, Dysphagia...
AEs leading to
discontinuation/dose reduction:
Excitement (2.2%)
Dysphagia (2.2%)
Sources:
90 mg 1 times / day multiple, oral
Recommended
Dose: 90 mg, 1 times / day
Route: oral
Route: multiple
Dose: 90 mg, 1 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Disc. AE: Neurologic symptoms, Hypertonia...
AEs leading to
discontinuation/dose reduction:
Neurologic symptoms (grade 3)
Hypertonia (grade 3)
Dysphagia
Autonomic dysfunction
QT interval prolonged
Ventricular arrhythmia
Torsade de pointes
Tardive dyskinesia
Neuroleptic malignant syndrome
Stroke
Venous thromboembolism
Sources:
15 mg 3 times / day multiple, oral
Studied dose
Dose: 15 mg, 3 times / day
Route: oral
Route: multiple
Dose: 15 mg, 3 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M
Food Status: UNKNOWN
Sources:
Disc. AE: Seizures...
AEs leading to
discontinuation/dose reduction:
Seizures (1.8%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Dysphagia 2.2%
Disc. AE
30 mg 3 times / day multiple, oral
Recommended
Dose: 30 mg, 3 times / day
Route: oral
Route: multiple
Dose: 30 mg, 3 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Excitement 2.2%
Disc. AE
30 mg 3 times / day multiple, oral
Recommended
Dose: 30 mg, 3 times / day
Route: oral
Route: multiple
Dose: 30 mg, 3 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Autonomic dysfunction Disc. AE
90 mg 1 times / day multiple, oral
Recommended
Dose: 90 mg, 1 times / day
Route: oral
Route: multiple
Dose: 90 mg, 1 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Dysphagia Disc. AE
90 mg 1 times / day multiple, oral
Recommended
Dose: 90 mg, 1 times / day
Route: oral
Route: multiple
Dose: 90 mg, 1 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Neuroleptic malignant syndrome Disc. AE
90 mg 1 times / day multiple, oral
Recommended
Dose: 90 mg, 1 times / day
Route: oral
Route: multiple
Dose: 90 mg, 1 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
QT interval prolonged Disc. AE
90 mg 1 times / day multiple, oral
Recommended
Dose: 90 mg, 1 times / day
Route: oral
Route: multiple
Dose: 90 mg, 1 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Stroke Disc. AE
90 mg 1 times / day multiple, oral
Recommended
Dose: 90 mg, 1 times / day
Route: oral
Route: multiple
Dose: 90 mg, 1 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Tardive dyskinesia Disc. AE
90 mg 1 times / day multiple, oral
Recommended
Dose: 90 mg, 1 times / day
Route: oral
Route: multiple
Dose: 90 mg, 1 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Torsade de pointes Disc. AE
90 mg 1 times / day multiple, oral
Recommended
Dose: 90 mg, 1 times / day
Route: oral
Route: multiple
Dose: 90 mg, 1 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Venous thromboembolism Disc. AE
90 mg 1 times / day multiple, oral
Recommended
Dose: 90 mg, 1 times / day
Route: oral
Route: multiple
Dose: 90 mg, 1 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Ventricular arrhythmia Disc. AE
90 mg 1 times / day multiple, oral
Recommended
Dose: 90 mg, 1 times / day
Route: oral
Route: multiple
Dose: 90 mg, 1 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Hypertonia grade 3
Disc. AE
90 mg 1 times / day multiple, oral
Recommended
Dose: 90 mg, 1 times / day
Route: oral
Route: multiple
Dose: 90 mg, 1 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Neurologic symptoms grade 3
Disc. AE
90 mg 1 times / day multiple, oral
Recommended
Dose: 90 mg, 1 times / day
Route: oral
Route: multiple
Dose: 90 mg, 1 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Seizures 1.8%
Disc. AE
15 mg 3 times / day multiple, oral
Studied dose
Dose: 15 mg, 3 times / day
Route: oral
Route: multiple
Dose: 15 mg, 3 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M
Food Status: UNKNOWN
Sources:
PubMed

PubMed

TitleDatePubMed
Methotrimeprazine-induced corneal deposits and cataract revealed by urine drug profiling test.
2010-11
Research on antipsychotics in India.
2010-01
An overview of Indian research in schizophrenia.
2010-01
Relationship between obesity and antipsychotic drug use in the adult population: a longitudinal, retrospective claim database study in Primary Care settings.
2008-02
Simple and simultaneous determination for 12 phenothiazines in human serum by reversed-phase high-performance liquid chromatography.
2007-07-01
Analysis of phenothiazines in human body fluids using disk solid-phase extraction and liquid chromatography.
2006-03-11
Correlative neuroanatomical and neuropharmacological study of tremor and catatonia in the monkey.
1971-05
The bucco-linguo-masticatory syndrome as a side-effect of neuroleptics therapy.
1967
Patents

Patents

Sample Use Guides

Adults: It is recommended to start treatment at a low dosage of about 5 mg per day in a single dose or in divided doses. This initial dosage is gradually increased by the same amount every 2 to 3 days until the usual effective dosage of 30 to 40 mg per day is reached. In some cases higher dosages of 90 mg or more per day, are necessary to control the psychotic manifestations. Children: In children over 10 years: Start treatment with a daily dosage of 1 to 3 mg following the method of treatment described for adults.
Route of Administration: Oral
In Vitro Use Guide
The effects of drugs on biochemical parameters of red blood cells were assessed using 100 ml human blood, which was obtained from a volunteer and diluted with 15 ml of 16 mM citric acid, 113 mM sodium citrate, 21 mM monosodium phosphate, 140 mM glucose, and 2 mM adenine at pH 7.4. Thioproperazine samples were added to 10-ml aliquots of blood to give a final concentration of 1 mM, and the blood was stored at 4 C. The pH of the blood was routinely measured, and 2-ml samples were taken. The cells were pelleted by centrifugation at 3000gma x for 5 rain, and the supernatants were removed. Two volumes of 15% (w/v) trichloroacetic acid were added to 1 vol of packed cells and, after standing on ice for 10 rain, the denatured protein was removed by centrifugation. The acid-soluble fraction was extracted four times with copious amounts of water-saturated diethyl ether to remove the trichloracetic acid and was assayed for 2,3-diphosphoglyceric acid levels using spectrophotometric methods
Name Type Language
THIOPROPERAZINE
INN   MI   WHO-DD  
INN  
Official Name English
THIOPROPERAZINE [MI]
Preferred Name English
Thioproperazine [WHO-DD]
Common Name English
thioproperazine [INN]
Common Name English
Classification Tree Code System Code
WHO-VATC QN05AB08
Created by admin on Mon Mar 31 18:06:17 GMT 2025 , Edited by admin on Mon Mar 31 18:06:17 GMT 2025
NCI_THESAURUS C29710
Created by admin on Mon Mar 31 18:06:17 GMT 2025 , Edited by admin on Mon Mar 31 18:06:17 GMT 2025
WHO-ATC N05AB08
Created by admin on Mon Mar 31 18:06:17 GMT 2025 , Edited by admin on Mon Mar 31 18:06:17 GMT 2025
Code System Code Type Description
EVMPD
SUB10983MIG
Created by admin on Mon Mar 31 18:06:17 GMT 2025 , Edited by admin on Mon Mar 31 18:06:17 GMT 2025
PRIMARY
CHEBI
59120
Created by admin on Mon Mar 31 18:06:17 GMT 2025 , Edited by admin on Mon Mar 31 18:06:17 GMT 2025
PRIMARY
DRUG CENTRAL
2635
Created by admin on Mon Mar 31 18:06:17 GMT 2025 , Edited by admin on Mon Mar 31 18:06:17 GMT 2025
PRIMARY
SMS_ID
100000082127
Created by admin on Mon Mar 31 18:06:17 GMT 2025 , Edited by admin on Mon Mar 31 18:06:17 GMT 2025
PRIMARY
RXCUI
10498
Created by admin on Mon Mar 31 18:06:17 GMT 2025 , Edited by admin on Mon Mar 31 18:06:17 GMT 2025
PRIMARY RxNorm
INN
911
Created by admin on Mon Mar 31 18:06:17 GMT 2025 , Edited by admin on Mon Mar 31 18:06:17 GMT 2025
PRIMARY
PUBCHEM
9429
Created by admin on Mon Mar 31 18:06:17 GMT 2025 , Edited by admin on Mon Mar 31 18:06:17 GMT 2025
PRIMARY
MERCK INDEX
m10780
Created by admin on Mon Mar 31 18:06:17 GMT 2025 , Edited by admin on Mon Mar 31 18:06:17 GMT 2025
PRIMARY Merck Index
CAS
316-81-4
Created by admin on Mon Mar 31 18:06:17 GMT 2025 , Edited by admin on Mon Mar 31 18:06:17 GMT 2025
PRIMARY
DRUG BANK
DB01622
Created by admin on Mon Mar 31 18:06:17 GMT 2025 , Edited by admin on Mon Mar 31 18:06:17 GMT 2025
PRIMARY
FDA UNII
YJ050AQ56X
Created by admin on Mon Mar 31 18:06:17 GMT 2025 , Edited by admin on Mon Mar 31 18:06:17 GMT 2025
PRIMARY
EPA CompTox
DTXSID1023655
Created by admin on Mon Mar 31 18:06:17 GMT 2025 , Edited by admin on Mon Mar 31 18:06:17 GMT 2025
PRIMARY
MESH
C084825
Created by admin on Mon Mar 31 18:06:17 GMT 2025 , Edited by admin on Mon Mar 31 18:06:17 GMT 2025
PRIMARY
ECHA (EC/EINECS)
206-262-4
Created by admin on Mon Mar 31 18:06:17 GMT 2025 , Edited by admin on Mon Mar 31 18:06:17 GMT 2025
PRIMARY
NCI_THESAURUS
C73292
Created by admin on Mon Mar 31 18:06:17 GMT 2025 , Edited by admin on Mon Mar 31 18:06:17 GMT 2025
PRIMARY
WIKIPEDIA
THIOPROPERAZINE
Created by admin on Mon Mar 31 18:06:17 GMT 2025 , Edited by admin on Mon Mar 31 18:06:17 GMT 2025
PRIMARY
ChEMBL
CHEMBL609109
Created by admin on Mon Mar 31 18:06:17 GMT 2025 , Edited by admin on Mon Mar 31 18:06:17 GMT 2025
PRIMARY